SCHEMBL10043697

SCHEMBL10043697

Cc1cc2c(cn1)cc(-c1cc(NC(=O)c3coc(C)n3)ccc1C)c(=O)n2C

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.43
GSK3B P49841 1/20 0.40
DYRK1A Q13627 1/20 0.40
BACE1 P56817 7/20 0.38
BACE2 Q9Y5Z0 2/20 0.37
RAF1 P04049 1/20 0.37
BRAF P15056 1/20 0.37
MAPK14 Q16539 1/20 0.36
ABL1 P00519 2/20 0.36
NPC1 O15118 2/20 0.36
MAPT P10636 2/20 0.36
RAB9A P51151 2/20 0.36
GAA P10253 1/20 0.36
FGFR1 P11362 3/20 0.36
SRC P12931 3/20 0.36
IRAK4 Q9NWZ3 1/20 0.36
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043691 0.88 NPC1 (0.48) SYKRAF1BRAFNPC1MAPT
SCHEMBL10043960 0.87 SYK (0.43) SYKBACE1RAF1BRAFMAPK14
SCHEMBL10043744 0.85 SYK (0.44) SYKBACE1NPC1RAB9AFGFR1
SCHEMBL10043746 0.85 GRM4 (0.48) SYKNPC1MAPTRAB9AGAA
SCHEMBL10043679 0.85 SYK (0.47) SYKBRAFMAPK14ABL1NPC1
SCHEMBL10043707 0.84 SYK (0.43) SYKGSK3BDYRK1ARAF1BRAF
SCHEMBL10043745 0.84 SYK (0.45) SYKBACE1BACE2MAPK14NPC1
SCHEMBL10043705 0.84 MAPT (0.54) SYKMAPK14ABL1NPC1MAPT
SCHEMBL10043673 0.83 SYK (0.46) SYKRAF1BRAFMAPK14ABL1
SCHEMBL10043740 0.83 RAF1 (0.43) SYKBACE1BACE2RAF1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885GSK3B 554/4885DYRK1A 335/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885GSK3B 554/4885DYRK1A 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.